See the DrugPatentWatch profile for aspirin

Aspirin is known to have antiplatelet effects, meaning it can prevent blood clots from forming by inhibiting the aggregation of platelets [1]. This property of aspirin is often utilized in the prevention and treatment of cardiovascular diseases. However, when it comes to the efficacy of other antiplatelet drugs, the interaction is complex and can be influenced by several factors.

According to DrugPatentWatch.com, aspirin is often combined with other antiplatelet drugs such as clopidogrel, prasugrel, and ticagrelor to treat conditions like acute coronary syndrome and peripheral artery disease [2]. The combination of aspirin with these drugs is generally recommended because it can provide additive or synergistic effects in inhibiting platelet aggregation, thereby reducing the risk of thrombotic events [3][4].

However, it is important to note that the concomitant use of aspirin and other antiplatelet drugs can also increase the risk of bleeding complications [5]. Therefore, the decision to use aspirin in combination with other antiplatelet drugs should be based on a careful evaluation of the potential benefits and risks for each individual patient [6].

In summary, aspirin can affect the efficacy of antiplatelet drugs by providing additive or synergistic effects in inhibiting platelet aggregation. However, the combination of aspirin with other antiplatelet drugs can also increase the risk of bleeding complications. Therefore, the use of aspirin in combination with other antiplatelet drugs should be based on a careful evaluation of the potential benefits and risks for each individual patient.

Sources:

1. Patrono C, Baich J, Garcia Rodriguez LA, Hirsh J, Roth G, Weitz JI. Aspirin and other antiplatelet agents. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine, 19e. McGraw-Hill; 2015.
2. DrugPatentWatch.com. Aspirin and Antiplatelet Drugs. <https://www.drugpatentwatch.com/drug/aspirin-and-antiplatelet-drugs>. Accessed March 15, 2023.
3. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717. doi:10.1056/NEJMoa052722
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706622
5. Bhatt DL, Emanuelsson H, Olsson SB, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2010;363(13):1179-1190. doi:10.1056/NEJMoa1009617
6. Bonaca MP, Bhatt DL, Cohen M, et al. Low-dose rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2015;373(13):1223-1233. doi:10.1056/NEJMoa1506383